pembrolizumab

You have access
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG

Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
You have access
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
Open Access
Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan
DAISUKE SANO, MOTOHIKO TOKUHISA, HIDEAKI TAKAHASHI, TAKASHI HATANO, GOSHI NISHIMURA, YASUSHI ICHIKAWA and NOBUHIKO ORIDATE

Anticancer Research September 2022, 42 (9) 4477-4484; DOI: https://doi.org/10.21873/anticanres.15948
You have access
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA

Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854
You have access
Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer
MOTOHIRO FUJIWARA, RYO FUJIWARA, TETSUYA URASAKI, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA

Anticancer Research April 2022, 42 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.15685
You have access
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638
You have access
Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, KEITA IZUMI, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, TOSHIHIKO IIZUKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research February 2022, 42 (2) 1131-1136; DOI: https://doi.org/10.21873/anticanres.15576
You have access
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma
TETSUYA YUMIOKA, MASASHI HONDA, RYUTARO SHIMIZU, SHOGO TERAOKA, NORIYA YAMAGUCHI, BUNYA KAWAMOTO, HIDETO IWAMOTO, SHUICHI MORIZANE, KATSUYA HIKITA and ATSUSHI TAKENAKA

Anticancer Research November 2021, 41 (11) 5767-5773; DOI: https://doi.org/10.21873/anticanres.15393
You have access
Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report
YOSUKE SHIONOYA, YOSHIHIKO HIROHASHI, HARUKA TAKAHASHI, MIDORI HASHIMOTO, KAORU NISHIYAMA, YASUNARI TAKAKUWA, MUNEHIDE NAKATSUGAWA, TERUFUMI KUBO, TAKAYUKI KANASEKI, TOMOHIDE TSUKAHARA and TOSHIHIKO TORIGOE

Anticancer Research July 2021, 41 (7) 3699-3706; DOI: https://doi.org/10.21873/anticanres.15161
You have access
Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma
YOSHIFUMI KADONO, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, TAIKI KAMIJIMA, CHIKASHI SETO, AKINOBU TAKANO, SATOSHI YOTSUYANAGI, RYUNOSUKE NAKAGAWA, TOHRU MIYAGI, SHUHEI AOYAMA, HIDEKI ASAHI, RIE FUKUDA and ATSUSHI MIZOKAMI

Anticancer Research March 2021, 41 (3) 1599-1606; DOI: https://doi.org/10.21873/anticanres.14921

Main menu

User menu

Search

pembrolizumab

Pages